NervGen Historical Income Statement
| NGEN Stock | CAD 3.11 0.21 7.24% |
Historical analysis of NervGen Pharma income statement accounts such as Other Operating Expenses of 27.8 M can show how well NervGen Pharma Corp performed in making a profits. Evaluating NervGen Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of NervGen Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining NervGen Pharma Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether NervGen Pharma Corp is a good buy for the upcoming year.
NervGen |
About NervGen Income Statement Analysis
NervGen Pharma Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to NervGen Pharma shareholders. The income statement also shows NervGen investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
NervGen Pharma Income Statement Chart
Add Fundamental
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on NervGen Pharma income statement and is an important metric when analyzing NervGen Pharma Corp profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most accounts from NervGen Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into NervGen Pharma Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NervGen Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, NervGen Pharma's Other Operating Expenses is fairly stable compared to the past year. Reconciled Depreciation is likely to climb to about 152.3 K in 2024, despite the fact that Operating Income is likely to grow to (16.9 M).
NervGen Pharma income statement Correlations
Click cells to compare fundamentals
NervGen Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NervGen Pharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Selling General Administrative | 3.4M | 5.0M | 5.9M | 6.3M | 9.6M | 4.9M | |
| Other Operating Expenses | 9.9M | 11.2M | 12.8M | 23.0M | 26.5M | 27.8M | |
| Operating Income | (9.9M) | (11.2M) | (12.9M) | (22.8M) | (17.8M) | (16.9M) | |
| Net Income From Continuing Ops | (9.8M) | (11.2M) | (12.7M) | (20.7M) | (22.4M) | (21.3M) | |
| Ebit | (9.9M) | (11.2M) | (12.9M) | (22.8M) | (20.5M) | (19.5M) | |
| Research Development | 6.4M | 6.2M | 6.9M | 16.6M | 8.0M | 7.1M | |
| Ebitda | (9.8M) | (11.1M) | (12.8M) | (22.7M) | (20.4M) | (19.4M) | |
| Total Operating Expenses | 9.9M | 11.2M | 12.8M | 23.0M | 17.8M | 11.9M | |
| Reconciled Depreciation | 38.2K | 39.6K | 42.6K | 115.1K | 145.0K | 152.3K | |
| Income Before Tax | (9.8M) | (11.2M) | (12.7M) | (20.7M) | (22.4M) | (21.3M) | |
| Net Income Applicable To Common Shares | (9.8M) | (11.2M) | (12.7M) | (20.7M) | (18.7M) | (17.7M) | |
| Net Income | (9.7M) | (11.2M) | (12.6M) | (18.1M) | (22.4M) | (21.3M) | |
| Depreciation And Amortization | 38.2K | 39.6K | 42.6K | 115.1K | 132.4K | 139K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.